Detailed information for compound 1496611

Basic information

Technical information
  • TDR Targets ID: 1496611
  • Name: N-[1-(2-bromo-4,5-diethoxyphenyl)ethyl]pyridi ne-3-carboxamide
  • MW: 393.275 | Formula: C18H21BrN2O3
  • H donors: 1 H acceptors: 2 LogP: 3.39 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCOc1cc(C(NC(=O)c2cccnc2)C)c(cc1OCC)Br
  • InChi: 1S/C18H21BrN2O3/c1-4-23-16-9-14(15(19)10-17(16)24-5-2)12(3)21-18(22)13-7-6-8-20-11-13/h6-12H,4-5H2,1-3H3,(H,21,22)
  • InChiKey: MCSXKLUSXPBPLS-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[1-(2-bromo-4,5-diethoxy-phenyl)ethyl]pyridine-3-carboxamide
  • N-[1-(2-bromo-4,5-diethoxyphenyl)ethyl]-3-pyridinecarboxamide
  • N-[1-(2-bromo-4,5-diethoxy-phenyl)ethyl]nicotinamide
  • MLS001178955
  • N-[1-(2-bromo-4,5-diethoxyphenyl)ethyl]nicotinamide
  • SMR000477026
  • AN-153/41789080

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens ataxin 2 Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni hypothetical protein 0.0231 1 0.5
Leishmania major PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative 0.0231 1 1
Trypanosoma cruzi DNA repair and recombination helicase protein PIF7, putative 0.0231 1 1
Entamoeba histolytica hypothetical protein, conserved 0.0231 1 0.5
Giardia lamblia Rrm3p helicase 0.0231 1 0.5
Leishmania major PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative 0.0231 1 1
Loa Loa (eye worm) hypothetical protein 0.003 0 0.5
Trypanosoma cruzi DNA repair and recombination helicase protein PIF6, putative 0.0231 1 1
Toxoplasma gondii LsmAD domain-containing protein 0.003 0 0.5
Plasmodium falciparum ataxin-2 like protein, putative 0.003 0 0.5
Trichomonas vaginalis conserved hypothetical protein 0.0231 1 0.5
Trypanosoma cruzi DNA repair and recombination helicase protein PIF7, putative 0.0231 1 1
Brugia malayi hypothetical protein 0.003 0 0.5
Plasmodium vivax ataxin-2 like protein, putative 0.003 0 0.5
Echinococcus multilocularis ATP dependent DNA helicase PIF1 0.0231 1 0.5
Trypanosoma brucei DNA repair and recombination helicase protein PIF7 0.0231 1 1
Entamoeba histolytica DNA repair and recombination protein, putative 0.0231 1 0.5
Plasmodium falciparum ataxin-2 like protein, putative 0.003 0 0.5
Trypanosoma brucei DNA repair and recombination helicase protein PIF6 0.0231 1 1

Activities

Activity type Activity value Assay description Source Reference
Potency (functional) 0.0075 uM PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) ChEMBL. No reference
Potency (functional) 23.1093 uM PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] ChEMBL. No reference
Potency (functional) 100 uM PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.